A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2006
11/29/2006	EP1726298A2 Oral liquid formulations containing citalopram
11/29/2006	EP1726296A1 Cosmetic or therapeutic combination preparation comprising theanine
11/29/2006	EP1726217A1 Method for production of arachidonic acid
11/29/2006	EP1725660A2 Multiple promoter expression cassettes for simultaneous delivery of rnai agents
11/29/2006	EP1725658A2 Materials and methods for treatment of allergic disease
11/29/2006	EP1725577A1 Antithrombotic compound
11/29/2006	EP1725569A1 Prodrugs of piperazine and substituted piperidine antiviral agents
11/29/2006	EP1725567A1 Spirocyclic cyclohexane derivatives with affinity to the orl-1 receptor
11/29/2006	EP1725565A2 Fused heterotricyclic compounds as inhibitors of 17b-hydroxysteroid dehydrogenase 3
11/29/2006	EP1725564A1 M3 muscarinic acetylcholine receptor antagonists
11/29/2006	EP1725562A1 Pyrrolopyrimidine derivatives
11/29/2006	EP1725556A1 Hiv integrase inhibitors
11/29/2006	EP1725555A1 Pyrrolopyridine-2-carboxylic acid hydrazides as inhibitors of glycogen phosphorylase
11/29/2006	EP1725554A1 Hiv integrase inhibitors
11/29/2006	EP1725553A1 Tetrahydropyridoindole derivatives
11/29/2006	EP1725552A1 New quaternized quinuclidine esters
11/29/2006	EP1725551A1 Oxidized thioether derivatives of styryl-azoles and their use as her tyrosine kinases inhibitors
11/29/2006	EP1725550A2 Pyrrole-derivatives as factor xa inhibitors
11/29/2006	EP1725549A1 Pentafluorosulfanyl compounds, their manufacture and use as pharmaceutical agents
11/29/2006	EP1725546A1 Pyrazolyl indolyl derivatives as ppar activators
11/29/2006	EP1725544A1 3-[4-heterocyclyl-1,2,3-triazol-1-yl]-n-aryl-benzamides as inhibitors of the cytokines production for the treatment of chronic inflammatory diseases
11/29/2006	EP1725543A1 4-benzimidazol-2-yl-pyridazine-3-one-derivatives, production and use thereof in medicaments
11/29/2006	EP1725542A1 Vla-4 antagonists
11/29/2006	EP1725540A1 Diaminopyrimidines as p2x3 and p2x2/3 antagonists
11/29/2006	EP1725538A1 Pyridazinone ureas as antagonists of a4 integrins
11/29/2006	EP1725537A1 Novel compounds as opioid receptor modulators
11/29/2006	EP1725534A1 Novel amido-substituted hydroxy-6-phenylphenanthridines and their use as pde4 inhibitors
11/29/2006	EP1725533A1 Novel thio containing hydroxy-6-phenylphenanthridines and their use as pde4 inhibitors
11/29/2006	EP1725532A1 Novel difluoroethoxy-substituted hydroxy-6-phenylphenanthridines and their use as pde4 inhibitors
11/29/2006	EP1725531A2 Inhibitors of dna methylation in tumor cells
11/29/2006	EP1725530A1 Organic compounds
11/29/2006	EP1725529A1 Bis bicyclic amides as vanilloid receptor ligands and their use in treatments of inflammatory and neuropatic pain
11/29/2006	EP1725528A2 Sulphonylpyrroles as hdac inhibitors
11/29/2006	EP1725525A1 Diphenylmethyl compounds useful as muscarinic receptor antagonists
11/29/2006	EP1725523A1 Ion channel modulators
11/29/2006	EP1725522A1 Aniline derivatives as selective androgen receptor modulators
11/29/2006	EP1725520A2 Formulation auxiliary agents (aminopropanoic acid derivative) in cosmetic or dermatoligical preparations
11/29/2006	EP1725519A1 Amino acid derivatives
11/29/2006	EP1725518A1 Pharmaceutical compounds
11/29/2006	EP1725295A2 Compositions and use of tyrosine kinase inhibitors to treat pathogenic infection
11/29/2006	EP1725275A1 Bone grafting material, comprising a porous carrier and at least one pyrrolindone, a method for its production and an implant
11/29/2006	EP1725267A2 Enzyme-prodrug therapy for prosthetic joint repair
11/29/2006	EP1725263A1 Stable, palatable syrup containing ibuprofen and method of its preparation
11/29/2006	EP1725252A2 Antitumour treatments with metxia-p450 and cyclophosphamide or 5t4 vaccine
11/29/2006	EP1725248A1 Preparations containing echinacea extracts and thiocyanate
11/29/2006	EP1725247A1 Polyphenols as an intravesical agent for the prevention of transitional cell tumor implantation
11/29/2006	EP1725245A2 Manganese and iron based compounds for elastogenesis and connective tissue treatment
11/29/2006	EP1725244A2 Method of preventing fibrin clots in pulmonary tissue through the use of aerosolized anticoagulants
11/29/2006	EP1725243A2 Boronate medicaments for preventing thrombosis during surgery
11/29/2006	EP1725242A2 Boronate medicaments suitable for short duration anticoagulation
11/29/2006	EP1725241A1 M3 muscarinic acetylcholine receptor antagonists
11/29/2006	EP1725240A1 Muscarinic acetylcholine receptor antagonists
11/29/2006	EP1725239A1 4-(sulfanyl-pyrimidin-4-ylmethyl)-morpholine derivatives and related compounds as gaba receptor ligands for the treatment of anxiety, depression and epilepsy
11/29/2006	EP1725238A2 M 3 muscarinic acetylcholine receptor antagonists
11/29/2006	EP1725237A2 Methods for treating alcoholism
11/29/2006	EP1725236A1 Novel m3 muscarinic acetylcholine receptor antagonists
11/29/2006	EP1725235A1 Piperidine derivatives useful as ccr3 antagonists
11/29/2006	EP1725234A1 Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects
11/29/2006	EP1725233A1 Sns-595 and methods of using the same
11/29/2006	EP1725232A1 (indol-3-yl)-heterocycle derivatives as agonists of the cannabinoid cb1 receptor
11/29/2006	EP1725231A1 Triazole, oxadiazole and thiadiazole derivatives as ppar modulators for the treatment of diabetes
11/29/2006	EP1725230A1 Methimazole derivatives and tautomeric cyclic thiones to inhibit cell adhesion
11/29/2006	EP1725229A1 Use of desoxypeganine for the treatment of schizophrenic psychoses
11/29/2006	EP1725228A2 Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma
11/29/2006	EP1725227A1 Use of new lipoxygenase inhibitors
11/29/2006	EP1725226A2 The treatment of inflammatory disorders and pain using beta-aminoalcohols
11/29/2006	EP1725225A1 Ambroxol for treating acute pains
11/29/2006	EP1725224A2 Methods and compositions comprising non-peptide small molecules that solubilize beta amyloid peptide fiber
11/29/2006	EP1725223A2 Use of antagonists of the cb1 receptor for the manufacture of a composition useful for the treatment of hepatic deseases
11/29/2006	EP1725222A2 Methods and compositions for treating or preventing psychiatric disorders with cox-2 inhibitors alone and in combination with antidepressant agents
11/29/2006	EP1725221A2 Use of mrp4-inhibitors for the treatment and/or prophylaxis of cardiovascular diseases
11/29/2006	EP1725218A1 Pharmaceutical composition comprising pimobendan
11/29/2006	EP1725217A1 Processes for the preparation of solid dosage forms of amorphous valganciclovir hydrochloride
11/29/2006	EP1725215A1 Method and apparatus for producing carrier complexes
11/29/2006	EP1725211A1 Peeling cosmetic method using a 8-hexadecene-1,16-dicarboxylic acid
11/29/2006	EP1725121A1 Novel dietary supplements or foodstuff based on unsaturated fatty acids and uses thereof
11/29/2006	EP1725120A1 Compositions, kits, and methods utilising an added boron source
11/29/2006	EP1725102A1 Hiv integrase inhibitors
11/29/2006	EP1725101A1 2-pyridinyl [7-(substituted-pyridin-4-yl) pyrazolo[1,5-a] pyrimidin-3-yl] methanones
11/29/2006	EP1725098A2 Benzamide and benzoate anti-hiv compounds
11/29/2006	EP1651642A4 Pna monomer and precursor
11/29/2006	EP1648408A4 Azepine derivatives as pharmaceutical agents
11/29/2006	EP1581506B1 Use of 2-amino-2h-quinazoline derivatives for producing therapeutic agents
11/29/2006	EP1570844B1 Composition comprising pseudoephedrine and domperidone for preventing snoring
11/29/2006	EP1553947A4 Quinazolinones and derivatives thereof as factor xa inhibitors
11/29/2006	EP1503987B1 Preparation of an anhydrous quinoline-based cetp inhibitor by crystallization
11/29/2006	EP1497656B1 Diagnosis of carcinoma using raig1 polypeptides
11/29/2006	EP1496051B1 Method for preparing 6-aminomethyl-6,11-dihydro-5h-dibenz(b,e)azepine
11/29/2006	EP1480624B1 Pharmaceutical tablet
11/29/2006	EP1414419B1 Pharmaceutical formulations comprising a cortisol synthesis inhibitor
11/29/2006	EP1409448B1 Process for the preparation of (r)- or (s)-aminocarnitine inner salt, the salts and derivatives thereof
11/29/2006	EP1401424B1 Carbamate compounds for use in preventing or treating psychotic disorders
11/29/2006	EP1397124B1 Use of antidiabetics for making a medicine with cicatrizing effect
11/29/2006	EP1248604B1 Combinations comprising dipeptidylpeptidase-iv inhibitors and antidiabetic agents
11/29/2006	EP1220911B1 P-glycoproteins and uses thereof
11/29/2006	EP1206529B1 UDP-N-ACETYLGLUCOSAMINE: GALACTOSE-BETA 1,3-N-ACETYLGALACTOSAMINE-ALPHA-R/(GlcNAc to GalNAc) BETA 1,6-N-ACETYLGLUCOSAMINYLTRANSFERASE, C2GnT3
11/29/2006	EP1198251B1 Combination of an anti-ep-cam antibody with a chemotherapeutic agent
11/29/2006	EP1146866B1 A method for treating patients with acne by administering a cyclic gmp pde inhibitor
11/29/2006	EP1117801B1 Polyketide synthase enzymes and recombinant dna constructs therefor, for the production of compounds related to fk-506 and fk-520
11/29/2006	EP1114028B1 Aza-bicycles which modulate the inhibition of cell adhesion

1 ... 3988 3989 3990 3991 3992 3993 3994 3995 3996 3997 3998 3999 4000 4001 4002 4003 4004 4005 4006 4007 4008 ... 7860